Masood Khan joins KCAS team

Becomes senior director of ligand binding assay services

KCAS, a US bioanalytical laboratory specialising in research and analytical services for pharmaceutical, biotech, animal health and medical device companies, has added Masood Khan to its growing team of experts. He will serve as senior director of ligand binding assay (LBA) services.

For nearly 20 years, Dr Khan has led wide-ranging research on strategic planning for LBA programmes, as well as the development of GLP-compliant and non-GLP assays for the conduct of ligand binding studies. He has chaired and organised many conferences and lectures at annual forums and meetings of the American Association of Pharmaceutical Scientists’ (AAPS) and has helped establish the LBAB-Focus Group, a specialist division of AAPS.

Dr Khan has worked in executive capacities for several contract research organisations (CROs) and pharmaceutical companies including MDS Life Sciences, Covance, NeuroBiotech, Medlmmune and most recently the National Institute of Health.

Dr Khan received his PhD in biochemistry from Aligarh University, India, and has conducted post-doctoral studies at the National Institute of Environmental Health Sciences in North Carolina and McGill University, Royal Victoria Hospital in Canada.

You may also like

Manufacturing

Automate Reactex glass reactor systems easily with Hitec Zang

Labtex, backed by more than 20 years of expertise in specialist laboratory and process chemistry equipment, is bringing advanced automation to its REACTEX glass reactor systems through innovative solutions from Hitec Zang
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Manufacturing

RION engages Lonza to scale manufacturing exosome based therapeutics

Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

The long and short of it: a new way to analyse ultrashort-, short- and long-chain PFAS simultaneously (part I)

SCIEX PFAS expert, Craig Butt (pictured), explores innovative methods that enable the rapid, sensitive detection and monitoring of ultrashort-, short- and long-chain PFAS in complex environmental matrices such as air and seawater
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
Subscribe now